| Completed | G-CSF-Induced Bone Pain and Supportive Care Approaches NCT07192770 | Ankara Etlik City Hospital | — |
| Not Yet Recruiting | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid NCT06926751 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in NCT06809101 | Pomeranian Medical University Szczecin | — |
| Recruiting | Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients w NCT06857292 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients NCT06649448 | Shandong Cancer Hospital and Institute | N/A |
| Recruiting | Breath Analysis for the Detection of Invasive Fungal Infections NCT06537726 | University of Zurich | — |
| Recruiting | Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor NCT07096479 | Anhui Provincial Hospital | — |
| Recruiting | Danish Elder Lymphoma Patient Hematopoietic Investigation NCT05245487 | Rigshospitalet, Denmark | — |
| Completed | Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer. NCT04914702 | Insel Gruppe AG, University Hospital Bern | — |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy T NCT04887831 | G1 Therapeutics, Inc. | Phase 2 |
| Unknown | Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma NCT04460508 | The First Hospital of Jilin University | Phase 2 |
| Completed | Study to Evaluate the Usability of PointCheck NCT04448314 | Leuko Labs, Inc. | — |
| Completed | Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy NCT04134429 | Insel Gruppe AG, University Hospital Bern | — |
| Unknown | Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia NCT03294577 | BeyondSpring Pharmaceuticals Inc. | Phase 3 |
| Unknown | Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Canc NCT04101760 | Lei Li | Phase 3 |
| Unknown | Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia NCT03846414 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | — |
| Unknown | Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer P NCT03823950 | University of Mississippi Medical Center | Phase 4 |
| Unknown | G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients NCT03793205 | Lei Li | Phase 4 |
| Unknown | Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis NCT03701841 | Anhui Provincial Hospital | — |
| Completed | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy P NCT03102606 | BeyondSpring Pharmaceuticals Inc. | Phase 3 |
| Completed | Plinabulin iv Solution in Prevention of TAC Induced Neutropenia NCT04227990 | BeyondSpring Pharmaceuticals Inc. | Phase 2 |
| Completed | Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patient NCT03251768 | Tianjin SinoBiotech Ltd. | Phase 2 |
| Terminated | Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced N NCT03559387 | Prolong Pharmaceuticals | Phase 2 |
| Completed | Community-Led Action Research in Oncology: Improving Symptom Management NCT03208816 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy P NCT04345900 | BeyondSpring Pharmaceuticals Inc. | Phase 2 |
| Unknown | Pegteograstim in Children With Solid Tumors NCT02787876 | Samsung Medical Center | Phase 2 |
| Completed | Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN NCT04460079 | Cinnagen | — |
| Completed | Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum NCT05512676 | Oslo University Hospital | — |
| Completed | Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia NCT02692742 | Myelo Therapeutics GmbH | Phase 2 |
| Unknown | Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Brea NCT02725606 | Jiangsu T-Mab Biopharma Co.,Ltd | Phase 1 |
| Completed | Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients NCT03246009 | Tianjin SinoBiotech Ltd. | Phase 1 |
| Completed | Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects NCT02643901 | Jiangsu T-Mab Biopharma Co.,Ltd | Phase 1 |
| Completed | Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Vo NCT02700360 | Enzychem Lifesciences Corporation | Phase 1 |
| Completed | A Safety and PK Study of EC-18 in Healthy Subjects NCT02496143 | Enzychem Lifesciences Corporation | Phase 1 |
| Completed | Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers NCT02532712 | Enzychem Lifesciences Corporation | Phase 1 |
| Completed | Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein NCT02465801 | Tianjin SinoBiotech Ltd. | Phase 2 |
| Completed | Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer NCT02251977 | Yuhong Li | Phase 3 |
| Terminated | Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study NCT02454530 | Pfizer | — |
| Completed | Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients NCT02104830 | Biocad | Phase 3 |
| Completed | Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors NCT02156388 | Jiangsu T-Mab Biopharma Co.,Ltd | Phase 1 |
| Completed | Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® NCT01735175 | Sandoz | Phase 3 |
| Completed | Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer NCT01569087 | Biocad | Phase 2 |
| Completed | Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim NCT01516736 | Sandoz | Phase 3 |
| Completed | Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia NCT01674855 | Dong-A ST Co., Ltd. | Phase 3 |
| Completed | GCPGC in Chemotherapy-induced Neutropenia NCT01328938 | Green Cross Corporation | Phase 2 / Phase 3 |
| Completed | Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia NCT01923545 | Dong-A ST Co., Ltd. | Phase 2 |
| Completed | Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel NCT01126190 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel NCT00837265 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) NCT00776165 | Shantha Biotechnics Limited | Phase 3 |
| Unknown | Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Ch NCT00501332 | Maxygen Holdings Ltd. | Phase 2 |